[go: up one dir, main page]

PE20060841A1 - Emplasto transdermico con ligandos especificos de progesterona a (prasl) como principio activo - Google Patents

Emplasto transdermico con ligandos especificos de progesterona a (prasl) como principio activo

Info

Publication number
PE20060841A1
PE20060841A1 PE2005001484A PE2005001484A PE20060841A1 PE 20060841 A1 PE20060841 A1 PE 20060841A1 PE 2005001484 A PE2005001484 A PE 2005001484A PE 2005001484 A PE2005001484 A PE 2005001484A PE 20060841 A1 PE20060841 A1 PE 20060841A1
Authority
PE
Peru
Prior art keywords
active principle
plaster
estradiol
polymer
prasl
Prior art date
Application number
PE2005001484A
Other languages
English (en)
Inventor
Hans-Peter Podhaisky
Stefan Bracht
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20060841A1 publication Critical patent/PE20060841A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

REFERIDA A UN EMPLASTO TRANSDERMICO QUE CONTIENE UN PRINCIPIO ACTIVO LIGANDO ESPECIFICO DE PROGESTERONA A TAL COMO UN COMPUESTO DE FORMULA I, DONDE R1 Y R2 SON H O F; R3 ES CH3 O CF3 Y AR ES UN COMPUESTO METILBENZOXAZINONA O BENZOFURANONA. DICHO EMPLASTO TRANSDERMICO ESTA COMPUESTO DE UNA CAPA BASE, AL MENOS UNA CAPA DE ADHESIVO QUE CONTIENE EL PRINCIPIO ACTIVO QUE SE ADHIERE A ELLA, LA CUAL COMPRENDE UN POLIMERO DE POLIISOBUTILENO (PIB), UN POLIMERO DE POLIACRILATO O UN POLIMERO EN BLOQUE DE ESTIRENO CON BUTADIENO O ISOPRENO (SBS O SIS), EN DONDE EL PRINCIPIO ACTIVO ESTA CONTENIDO EN UNA CONCENTRACION DEL 0,1% AL 10%, RESPECTO DEL PESO TOTAL DE LA MATRIZ DE ADHESIVO, ASI COMO UNA PELICULA PROTECTORA SEPARABLE. EL EMPLASTO TAMBIEN PUEDE CONTENER 17-BETA-ESTARDIOL, ETINILESTRADIOL, VALERATO DE ESTRADIOL, CIPIONATO DE ESTRADIOL, ACETATO DE ESTRADIOL O BENZOATO DE ESTRADIOL. DICHO EMPLASTO ES UTIL PARA LA TERAPIA DE REEMPLAZO HORMONAL Y EL CONTROL DE LA FERTILIDAD
PE2005001484A 2004-12-20 2005-12-16 Emplasto transdermico con ligandos especificos de progesterona a (prasl) como principio activo PE20060841A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004062182A DE102004062182B4 (de) 2004-12-20 2004-12-20 Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff

Publications (1)

Publication Number Publication Date
PE20060841A1 true PE20060841A1 (es) 2006-09-14

Family

ID=35559357

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001484A PE20060841A1 (es) 2004-12-20 2005-12-16 Emplasto transdermico con ligandos especificos de progesterona a (prasl) como principio activo

Country Status (20)

Country Link
EP (1) EP1671626A1 (es)
JP (1) JP2008524144A (es)
KR (1) KR20070089241A (es)
CN (1) CN101102754A (es)
AR (1) AR052168A1 (es)
AU (1) AU2005318548A1 (es)
BR (1) BRPI0519143A2 (es)
CA (1) CA2591076A1 (es)
CR (1) CR9207A (es)
DE (1) DE102004062182B4 (es)
EA (1) EA200701222A1 (es)
IL (1) IL183935A0 (es)
MX (1) MX2007007418A (es)
NO (1) NO20073768L (es)
PA (1) PA8657401A1 (es)
PE (1) PE20060841A1 (es)
TW (1) TW200633732A (es)
UY (1) UY29263A1 (es)
WO (1) WO2006066788A1 (es)
ZA (1) ZA200705991B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182949A1 (en) * 2008-05-30 2011-07-28 Jiashang Tang Stabilized transdermal drug delivery system
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
CN103893189B (zh) * 2012-12-26 2019-04-23 江苏康倍得药业股份有限公司 含雌二醇的药物组合物及其制备与应用
US20220219104A1 (en) * 2019-05-13 2022-07-14 Toyobo Co., Ltd. Filter medium for filter and filter

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2065311C (en) * 1989-09-08 2000-01-11 Chia-Ming Chiang Solid matrix system for transdermal drug delivery
DE4309830C1 (de) * 1993-03-26 1994-05-05 Lohmann Therapie Syst Lts Wirkstoffpflaster für die Abgabe von Estradiol an die Haut
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
DE19830732B4 (de) * 1998-07-09 2008-11-13 Lts Lohmann Therapie-Systeme Ag Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung
DE19830649C2 (de) * 1998-07-09 2003-04-10 Lohmann Therapie Syst Lts Topisches Pflaster mit nichtsteroidalen Antirheumatika mit Säuregruppe
DE10012908B4 (de) * 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
HRP20040923A2 (en) * 2002-03-11 2004-12-31 Schering Ag 5-{2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions

Also Published As

Publication number Publication date
CR9207A (es) 2007-11-23
AU2005318548A1 (en) 2006-06-29
CN101102754A (zh) 2008-01-09
PA8657401A1 (es) 2006-07-03
EP1671626A1 (de) 2006-06-21
JP2008524144A (ja) 2008-07-10
TW200633732A (en) 2006-10-01
WO2006066788A1 (de) 2006-06-29
MX2007007418A (es) 2007-08-17
UY29263A1 (es) 2006-06-30
IL183935A0 (en) 2007-10-31
BRPI0519143A2 (pt) 2008-12-30
ZA200705991B (en) 2009-01-28
EA200701222A1 (ru) 2007-12-28
AR052168A1 (es) 2007-03-07
CA2591076A1 (en) 2006-06-29
DE102004062182B4 (de) 2007-06-06
DE102004062182A1 (de) 2006-06-29
NO20073768L (no) 2007-07-19
KR20070089241A (ko) 2007-08-30

Similar Documents

Publication Publication Date Title
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
CA2762981C (en) Amorphous drug transdermal systems, manufacturing methods, and stabilization
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
WO2005002482A8 (en) Transdermal hormone delivery system: compositions and methods
ATE217793T1 (de) Transdermales pflaster des matrixtyps für steroidhormone
WO2007009730A8 (de) Polymerfilm für transdermale pflaster mit pharmazeutischem wirkstoff
HRP20100254T1 (hr) Transdermalni sustav za davanje gestodena
TW200716137A (en) Tanaproget compositions containing ethinyl estradiol
PE20090938A1 (es) Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
WO2007092284A3 (en) Low dose no donor-containing transdermal patch
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
PE20040157A1 (es) Progestinas no esteroides
AR051322A1 (es) Composiciones de amitraz
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
PE20060841A1 (es) Emplasto transdermico con ligandos especificos de progesterona a (prasl) como principio activo
Gompel et al. Tibolone actions on normal and breast cancer cells
PE20070192A1 (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
Augusto et al. Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells
WO2005077968A3 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
PE20070432A1 (es) Dispositivos de administracion transdermicas de farmacos que contienen o-desmetilvenlafaxina (odv) o sus sales
AR036970A1 (es) Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion
AR046458A1 (es) Composiciones que comprenden compuestos organicos
BRPI0417530A (pt) liberação transdérmica de hormÈnios sem a necessidade de melhoradores de penetração
PA8633601A1 (es) Profarmacos de esteroides con accion androgenica

Legal Events

Date Code Title Description
FC Refusal